Natera Inc Stock Price, News & Analysis

Natera (NASDAQ: NTRA) reported strong Q1 2025 financial results with total revenues of $501.8 million, up 36.5% year-over-year. The company achieved significant growth across key metrics: product revenues increased 37.1% to $500.0 million, gross margin improved to 63.1% from 56.7%, and processed 855,100 tests, a 16.2% increase. Notably, oncology tests grew 46.1% to 167,700. The company generated positive cash flow of $23.2 million. Despite higher operating expenses of $395.9 million, Natera reported a reduced net loss of $66.9 million ($0.50 per share). The company maintains a strong financial position with $991.6 million in cash and investments. For 2025, Natera projects total revenue between $1.94-$2.02 billion with positive net cash inflow.

Natera (NASDAQ: NTRA) will present multiple datasets at the 2025 ESMO Breast Cancer Annual Congress in Munich, showcasing results from the I-SPY 2 clinical trial. The study of 712 early-stage, high-risk breast cancer patients revealed that Signatera-positive patients had 3x higher recurrence risk compared to Signatera-negative patients. Key findings show that higher ctDNA quantities at diagnosis correlated with increased recurrence risk, and Signatera status emerged as the most significant predictor of distant recurrence free survival (DRFS). The research marks the first demonstration of pre-treatment absolute ctDNA quantity correlating with clinical outcomes in breast cancer. Natera will present six abstracts total, including real-world evidence from their database of over 200,000 cancer patients.

Natera (NASDAQ: NTRA) has published a new study in the American Journal of Transplantation demonstrating superior performance of its Prospera Heart test with DQS in detecting transplant rejection. The study analyzed 808 test samples from 187 heart transplant patients and showed significant improvements over traditional dd-cfDNA percentage testing, including: - Sensitivity increased to 86.5% (from 78.2%) - Specificity improved to 83.6% (from 76.9%) - 37.3% reduction in false positives - Area under curve (AUC) increased to 0.881 (from 0.865) The Prospera with DQS method combines donor fraction and donor quantity score to deliver a single result for assessing both antibody mediated rejection (AMR) and acute cellular rejection (ACR). This advancement could help reduce the need for invasive endomyocardial biopsies in heart transplant patients.

Natera (NASDAQ: NTRA) announced results from a Stanford-led study evaluating its Signatera molecular residual disease (MRD) test in sarcoma patients. The study, the largest of its kind, analyzed over 2,100 samples from 200+ sarcoma patients, demonstrating outstanding performance with 89% overall sensitivity and 100% specificity. For leiomyosarcoma, the most common subtype studied, the test showed 93% sensitivity and 100% specificity, with 90% correlation to treatment response.

The study's significance lies in addressing the challenges of monitoring sarcomas, which comprise over 70 distinct subtypes affecting approximately 17,000 new cases annually in the US. The research validates Signatera's effectiveness in noninvasively detecting disease recurrence and monitoring treatment response across various sarcoma subtypes. The team plans to launch a prospective study to further demonstrate clinical utility.

Natera (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing, has scheduled its first quarter 2025 earnings release for May 8, 2025, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day. Investors can access the conference call through domestic (1-888-596-4144) or international (1-646-968-2525) dial-in numbers using conference ID 7684785. A webcast replay will be available at investor.natera.com.

Natera has announced significant results from its DEFINE-HT clinical trial in heart transplantation, presented at the International Society for Heart and Lung Transplantation Annual Meeting. The study evaluated their Prospera Heart test with donor quantity score (DQS) in monitoring heart transplant outcomes.

Key findings from the trial, which analyzed over 1,100 donor-derived cell-free DNA (dd-cfDNA) samples, showed:

• Patients with elevated dd-cfDNA levels had 2.56 times higher risk of adverse events
• The test predicted graft dysfunction 3 times more effectively than traditional biopsy
• Prospera with DQS showed stronger correlation with clinical outcomes versus donor fraction alone

The study positions Prospera as a potential alternative to invasive endomyocardial biopsies (EMB), with ongoing research through the ACES-EMB study comparing both methods. This advancement represents a significant step toward less invasive transplant monitoring approaches.

Natera (NASDAQ: NTRA) has announced the broad clinical launch of its ultra-sensitive Signatera Genome MRD test for physicians across the United States. The launch is backed by extensive validation data from over 3,000 plasma samples across multiple cancer types, including breast, colorectal, non-small cell lung cancer, melanoma, and renal cell carcinoma.

The study, to be presented at the 2025 ASCO Annual Meeting, demonstrates Signatera Genome's ability to detect circulating tumor DNA (ctDNA) ahead of clinical recurrence. Patients testing Signatera-positive after surgery showed inferior recurrence-free survival compared to Signatera-negative patients across all cancer types studied.

The test utilizes Natera's patented multiplex PCR and next-generation sequencing technology, capable of detecting tumor DNA at frequencies as low as 1 part per million, with an RUO version detecting below this threshold.

Natera (NASDAQ: NTRA) has announced its upcoming participation at the 2025 AACR Annual Meeting in Chicago, where data from 8 studies will be presented. The presentations will showcase research utilizing Natera's proprietary real-world database and Signatera™ testing.

Key highlights include:

• An oral presentation on large-scale genomic profiling of colorectal cancer, analyzing mutational landscapes across clinical and molecular subgroups using data from over 73,000 patients
• Poster presentations examining genomic patterns in 30,000+ breast cancer patients and 8,000+ gynecologic cancer patients
• Research on improving immunotherapy response prediction through enhanced neoantigen identification
• Additional studies on esophageal cancer, sarcoma, and colorectal cancer validating Signatera's clinical effectiveness

Natera (NASDAQ: NTRA) announced upcoming presentation of results from the DEFINE-HT study at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. The study is the first prospective, multicenter trial evaluating the association between donor-derived cell-free DNA (dd-cfDNA) and clinical outcomes in heart transplant recipients using Prospera Heart with Donor Quantity Score (DQS).

The trial included over 1,100 dd-cfDNA tests, comparing Prospera testing with traditional rejection surveillance monitoring and endomyocardial biopsies for up to one year post-transplant. The research aims to determine if Prospera outperforms biopsy in predicting graft dysfunction and whether its proprietary two-threshold algorithm shows stronger correlation with clinical outcomes than dd-cfDNA percentage alone.